Erratum: Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs (The Lancet (2015) 386(9990) (303–310) (S0140673615602458) (10.1016/S0140-6736(15)60245-8));Oral anticoagulants for stroke prevention in atrial fibrillation: Current status, special situations, and unmet needs

The Lancet

Volumn 386, Issue 9990, 2015, Pages 303-310

  Verheugt, Freek W A ^a   Granger, Christopher B ^b  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; EDOXABAN; GLYCOPROTEIN P INHIBITOR; PRESCRIPTION DRUG; QUINIDINE; VERAPAMIL;

AGE; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DEVICE THERAPY; DRUG EFFICACY; DRUG SUBSTITUTION; EVIDENCE BASED PRACTICE; FOOD DRUG INTERACTION; HEART VALVE PROSTHESIS; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; STROKE PATIENT; SURGERY; VALVULAR HEART DISEASE; AGED; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; CONGENITAL MALFORMATION; DRUG INTERACTION; HEART VALVE; HEMORRHAGE; NEEDS ASSESSMENT; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PROCEDURES; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; DRUG SUBSTITUTION; ELECTRIC COUNTERSHOCK; HEART VALVE PROSTHESIS; HEART VALVES; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; NEEDS ASSESSMENT; PERIOPERATIVE CARE; STROKE;

EID: 84937642709     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61280-6     Document Type: Erratum

References (51)

1. DB Matchar, GP Samsa, SJ Cohen, EZ Oddone, AE Jurgelski Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial Am J Med 113 2002 42 51
2. P Gallego, V Roldán, F Marin et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am J Med 127 2014 1083 1088
3. AJ Camm, GYH Lip, R De Caterina the ESC Committee for Practice Guidelines (CPG) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
4. J Oldgren, JS Healey, M Ezekowitz the RE-LY Atrial Fibrillation Registry Investigators Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry Circulation 129 2014 1568 1576
5. SJ Connolly, MD Ezekowitz, S Yusuf the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
6. MR Patel, KW Mahaffey, J Garg the ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
7. CB Granger, JH Alexander, JJV McMurray the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
8. RP Giugliano, CT Ruff, E Braunwald the ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
9. S Shore, EP Carey, MP Turakhia et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration Am Heart J 167 2014 810 817
10. A Gorst-Rasmussen, F Skjøth, TB Larsen, LH Rasmussen, GY Lip, DA Lane Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study J Thromb Haemost 2015 10.1111/jth.12845 published online Jan 16.
11. S Chatterjee, P Sardar, JS Giri, J Ghosh, D Mukherjee Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101 801 patients Mayo Clin Proc 89 2014 896 907
12. CT Ruff, RP Giugliano, E Braunwald et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
13. SJ Connolly, L Wallentin, MD Ezekowitz et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study Circulation 128 2013 237 243
14. FWA Verheugt Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd? Eur Heart J 34 2013 1618 1620
15. C Kasmeridis, S Apostolakis, L Ehlers, LH Rasmussen, G Boriani, GY Lip Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants Pharmacoeconomics 31 2013 971 980
16. P Sardar, S Chatterjee, WC Wu et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons PLoS One 8 2013 e77694
17. DJ Graham, ME Reichman, M Wernecke et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation Circulation 131 2015 157 164
18. J Beyer-Westendorf, V Gelbricht, K Förster et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry Eur Heart J 35 2014 1888 1896
19. CT January, LS Wann, JS Alpert the ACC/AHA Task Force Members 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society Circulation 130 2014 2071 2104
20. SA LaHaye, SL Gibbens, DG Ball, AG Day, JB Olesen, AC Skanes A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation Eur Heart J 33 2012 2163 2171
21. I Savelieva, AJ Camm Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation Clin Cardiol 37 2014 32 47
22. JW Eikelboom, L Wallentin, SJ Connolly et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
23. S Halvorsen, D Atar, H Yang et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial Eur Heart J 35 2014 1864 1872
24. JL Halperin, GJ Hankey, DM Wojdyla the ROCKET AF Steering Committee and Investigators Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) Circulation 130 2014 138 146
25. R Cappato, MD Ezekowitz, AL Klein the X-VeRT Investigators Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur Heart J 35 2014 3346 3355
26. SJ Connolly, J Pogue, RG Hart the ACTIVE Investigators Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
27. SJ Connolly, J Eikelboom, C Joyner the AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
28. H Heidbuchel, P Verhamme, M Alings the European Heart Rhythm Association European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
29. A Cuker, DM Siegal, MA Crowther, DA Garcia Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants J Am Coll Cardiol 64 2014 1128 1139
30. PA Reilly, T Lehr, S Haertter the RE-LY Investigators The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 2014 321 328
31. ES Eerenberg, PW Kamphuisen, MK Sijpkens, JC Meijers, HR Buller, M Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
32. F Schiele, J van Ryn, K Canada et al. A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
33. G Lu, FR DeGuzman, SJ Hollenbach et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 2013 446 451
34. JE Ansell, SH Bakhru, BE Laulicht et al. Use of PER977 to reverse the anticoagulant effect of edoxaban N Engl J Med 371 2014 2141 2142
35. AL Dans, SJ Connolly, L Wallentin et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
36. JH Alexander, RD Lopes, L Thomas et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 35 2014 224 232
37. R Nagarakanti, MD Ezekowitz, J Oldgren et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
38. JP Piccini, SR Stevens, Y Lokhnygina the ROCKET AF Steering Committee & Investigators Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
39. G Flaker, RD Lopes, SM Al-Khatib the ARISTOTLE Committees and Investigators Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 2014 1082 1087
40. L Di Biase, JD Burkhardt, P Santangeli et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial Circulation 129 2014 2638 2644
41. JS Kim, F She, K Jongnarangsin et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
42. D Lakkireddy, YM Reddy, L Di Biase et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 59 2012 1168 1174
43. ML Hansen, R Sørensen, MT Clausen et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 2010 1433 1441
44. S Windecker, P Kolh, F Alfonso the Authors/Task Force members 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
45. WJM Dewilde, T Oirbans, FWA Verheugt the WOEST study investigators Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
46. GY Lip, S Windecker, K Huber the Document Reviewers Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J 35 2014 3155 3179
47. G Breithardt, H Baumgartner, SD Berkowitz the ROCKET AF Steering Committee & Investigators Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial Eur Heart J 35 2014 3377 3385
48. JW Eikelboom, SJ Connolly, M Brueckmann the RE-ALIGN Investigators Dabigatran versus warfarin in patients with mechanical heart valves N Engl J Med 369 2013 1206 1214
49. G Flaker, RD Lopes, E Hylek the ARISTOTLE Committees and Investigators Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial J Am Coll Cardiol 64 2014 1541 1550
50. CB Granger, RD Lopes, M Hanna et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial Am Heart J 169 2015 25 30
51. JW Eikelboom, T Vanassche, SJ Connolly Switching patients from blinded study drug to warfarin at the end of the ENGAGE AF-TIMI 48 trial: setting a new standard J Am Coll Cardiol 64 2014 585 587